Fatty acids linked to cardiovascular mortality are associated with risk factors

Sven O. E. Ebbesson, Venkata S. Voruganti, Paul B. Higgins, Richard R. Fabsitz, Lars O. Ebbesson, Sandra Laston, William S. Harris, John Kennish, Benjamin D. Uman, Hong Wang, Richard B. Devereux, Peter M. Okin, Neil J. Weissman, Jean W. MacCluer, Jason G. Umans and Barbara V. Howard

Background. Although saturated fatty acids (FAs) have been linked to cardiovascular mortality, it is not clear whether this outcome is attributable solely to their effects on low-density lipoprotein cholesterol (LDL-C) or whether other risk factors are also associated with FAs. The Western Alaskan Native population, with its rapidly changing lifestyle, shift in diet from unsaturated to saturated fatty acids and dramatic increase in cardiovascular disease (CVD), presents an opportunity to elucidate any associations between specific FAs and known CVD risk factors.

Objective. We tested the hypothesis that the specific FAs previously identified as related to CVD mortality are also associated with individual CVD risk factors.

Methods. In this community-based, cross-sectional study, relative proportions of FAs in plasma and red blood cell membranes were compared with CVD risk factors in a sample of 758 men and women aged ≥ 35 years. Linear regression analyses were used to analyze relations between specific FAs and CVD risk factors (LDL-C, high-density lipoprotein cholesterol, triglycerides, C-reactive protein, systolic blood pressure, diastolic blood pressure, heart rate, body mass index, fasting glucose and fasting insulin, 2-hour glucose and 2-hour insulin).

Results. The specific saturated FAs previously identified as related to CVD mortality, the palmitic and myristic acids, were adversely associated with most CVD risk factors, whereas unsaturated linoleic acid (18:2n-6) and the marine n-3 FAs were not associated or were beneficially associated with CVD risk factors.

Conclusions. The results suggest that CVD risk factors are more extensively affected by individual FAs than hitherto recognized, and that risk for CVD, MI and stroke can be reduced by reducing the intake of palmitate, myristic acid and simple carbohydrates and improved by greater intake of linoleic acid and marine n-3 FAs.

Keywords: Alaska Natives; cardiovascular risk factors; dietary fat consumption; fatty acids; fish oil consumption; Inuit; saturated fatty acids

Received: 1 April 2015; Revised: 15 July 2015; Accepted: 16 July 2015; Published: 12 August 2015
has emerged that unsaturated FAs (linoleic acid [LA] and long-chain omega-3 FAs) are associated with lower CVD mortality (3,5–7). The Uppsala Longitudinal Study of 2,000 Adult Men (ULSAM) found that serum cholesterol ester FA profiles were related to CV and total mortality over 30 years (3). The saturated FAs (myristic [14:0]) and palmitic [16:0] acids and the unsaturated FAs (palmitoleic [16:1], γ-linolenic [18:3-6] and dihomo-γ-linolenic [20:3-6] FAs) (3) also were associated with CV mortality, whereas LA (18:2-6) concentration was negatively associated with 30-year CV and total mortality (3).

CVD is a multi-factorial disease, involving inflammation (8,9), hypertension (10), obesity (11,12), insulin resistance (13,14), diabetes (15,16), elevated heart rate (17–19), low high-density lipoprotein cholesterol (HDL-C) (20), high low-density lipoprotein cholesterol (LDL-C) (20) and/or high triglycerides (21).

Several randomized trials of the associations of saturated and unsaturated fatty acids and CVD have been conducted (22–27). Early studies substituting polyunsaturated fat for saturated fat showed reduction in CVD for high-risk participants. Later studies have focused on omega 3 fats; while these reports have not been consistent, the consensus is that omega 3 fats may lower the risk of sudden death in patients with CVD (5,28).

Investigators have suggested that LDL-C concentration is the main mediator between dietary saturated FAs and CVD (29–31), but other risk factors, such as insulin resistance, inflammation and endothelial function, are also affected by FAs (13,14,32). Therefore, the following questions arise: (a) which FAs are associated with specific CVD risk factors and (b) what is the most clinically relevant measure of FA status – its relative per cent composition in red blood cell (RBC) membranes or its concentrations in plasma (33).

The Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study allows examination of these relationships in a population living in isolated villages along the northwest coast of Alaska. This population is currently undergoing a radical dietary change from traditional Native Alaskan foods, available primarily from the sea, to store-bought Western foods. This change involves a shift in dietary fat consumption from unsaturated FAs found in fish and sea mammals (34,35) to saturated FAs from farm animals, dairy products and manufactured fats (e.g. shortening). CVD incidence is changing concurrently. Whereas it was rare 40 years ago (<1/1,000) (36), CVD prevalence among Alaska Natives is now higher than that of the U.S. White population (37), and the prevalence and extent of carotid plaque in Western Alaskan Natives exceeds that of the U.S. White and African American populations (38) and is associated with blood concentrations of the saturated palmitic and myristic acids (39). Finally, stroke incidence in this population is 50% higher than that of the general U.S. population (40).

Measures of FAs used in previous studies range from dietary estimates, usually by food frequency questionnaire (FFQ) or multiple 24-hour recalls (3,41,42), to analyses of FA content in RBCs (35) or plasma (3,35) or through analyses of plasma lipid classes (either phospholipids or cholesterol esters) (3,43). Measurement errors and interpretation of all these measures vary. FFQs, however, may provide less reliable estimates of dietary FA intake than methods that measure FAs in blood (3,35,43) because they involve inaccuracies of memory, the inability of any questionnaire to completely reflect intake and because of incomplete nutritional databases, especially for traditional Alaska Native foods. The current study has, thus, been limited to analyses of FAs in plasma and RBCs (35), as these measures reflect the interplay between dietary and metabolic processes (44). Both of these measures have been validated as markers of intake of long-chain omega-3 FAs, trans FAs and, to some extent, LA (33–35).

Plasma concentrations of mono and saturated FAs do not entirely reflect diet as they can be modified by endogenous synthesis of carbohydrates (3), although this process is limited in those consuming high-fat Western diets (3). The total plasma FA biomarker used in the present study was used successfully as a biomarker previously in this population in a pilot intervention to reduce saturated fat consumption (34). This 4-year intervention resulted in a relative decrease of palmitate (16:0; p = 0.02) concomitant with improved glucose tolerance (p = 0.006), fasting glucose (p = 0.0001), LDL cholesterol (p = 0.0001) and diastolic blood pressure (p = 0.0007), all without weight loss.

Patients and methods

Study population

A total of 1,214 predominantly Inupiat people > 17 years of age from 9 villages in the Norton Sound Region of Alaska were examined between 2000 and 2004 for CVD and associated risk factors (45). In 7 of the 9 villages, an average of 82.6% of eligible residents participated (46). Screenings were terminated early in 2 additional villages, when the study reached its recruitment goal. From the sample of 1,214 participants, all participants ≥35 years of age (N = 819; 361 men and 458 women) underwent assessment of total plasma and RBC FAs; those with previously diagnosed diabetes mellitus (DM) and on medication for DM (N = 61) were excluded, yielding a study population of 758. The study was approved by the Research Ethics Review Board of the Norton Sound Health Corporation and by the institutional review boards of MedStar Health Research Institute and Texas Biomedical Research Institute. All participants provided informed consent.
**Study examination**

The GOCADAN exam (45) consisted of a personal interview (including lifestyle assessment, medical history and medication use), physical examination (including ultrasound assessment of atherosclerosis in the carotid arteries), nutritional interview using a validated FFQ (42), anthropometric measurements (45), blood pressure (BP) measurements (45), heart rate measurement (18,19), electrocardiogram (ECG) (19,45), blood sampling, a Rose questionnaire (45), a Modifiable Activity Questionnaire (45), behavioural measures (45) and laboratory analyses (45). The methods for plasma and RBC FA composition have been described (19,35). Apolipoprotein E (ApoE) phenotype was determined in whole plasma by a modification of the Kamboh et al. method, in which 2 hours of isoelectric focusing are followed by immunoblotting to visualize the ApoE bands (45). Serum C-reactive protein (CRP) was assayed as described previously (8). Participants with CRP > 10 (1.7% of sample) were excluded from the CRP analyses.

**Statistical analysis**

Means, standard deviations and 95% confidence intervals were calculated to describe the population's characteristics. Concentrations of FAs in plasma and RBC membranes were compared with CVD risk factors in a sample of 758 men and women aged > 34 years without diabetes, as defined by American Diabetes Association criteria (47). Prior to conducting analyses, distributional properties of all traits were evaluated. All values beyond 4 standard deviations were removed, and the remaining traits were transformed by inverse normalization prior to analysis to meet assumptions of normality.

While a correction for multiple testing was considered, it would have been inappropriate when the number of true positives (i.e. true biological associations that are also statistically significant) was likely to be a large percentage of the multiple tests. For the current analysis, a Bonferroni correction was not applied, because (a) RBC FA concentrations are less associated with some risk factors than those in plasma and (b) the Bonferroni adjustment is conservative and tends to produce false negatives. The conclusions expressed in this article are based on the plasma and RBC FA data without Bonferroni adjustment, in concurrence with other studies of individual variables (3,18,19,21,33,35). In addition, associations were first identified by individual testing of each FA and risk factor adjusted only for age. This approach provided additional confidence in the final results and conclusions.

**Statistical modelling**

The CVD risk factors were adjusted for age, sex, age², age × sex, age³ × sex, current smoking (Y/N), cholesterol medication and “physical activity” metabolic equivalents (METs). The age-squared covariate was included to account for the effect of age, which may have a non-linear relationship with the lipids. BP was adjusted for BP medication, and LDL-C and HDL-C were adjusted for ApoE phenotype. CVD risk factors evaluated were heart rate, systolic BP (SBP), diastolic BP (DBP), mean arterial pressure, HDL-C, LDL-C, triglycerides, CRP, 2-hour glucose, 2-hour insulin, fasting glucose, fasting insulin and body mass index (BMI).

**Bivariate analyses**

Bivariate analyses were conducted with Sequential Oligogenic Linkage Analysis Routines (SOLAR; Texas Biomedical Research Institute, San Antonio, TX) (48). Multiple linear regression analyses accounting for correlations among family members were used to analyze associations of CVD risk factors with specific FAs, after adjustment for relevant covariates.

Phenotypic correlations were computed between FAs and CVD risk factors (49).

**Results**

Population characteristics of the study sample are shown (Table I). Those of the full GOCADAN sample have been described (19,35,38,45). Previous data have shown median calories consumed from fat in the 35–40% range, with about 25% of the population maintaining a subsistence diet with saturated fat <10% of energy intake (42). Smoking rates are high, medication usage is low and the women have higher BMIs than the men but similar waist circumferences. Women have higher fasting insulin, heart rate and HDL-C than the men. The relevant dietary components of this cohort have been described elsewhere (42). The 3 top sources of saturated FAs (myristic, palmitic and stearic acids) found in the Western Alaskan Native diet are from store-bought foods, mostly butter, vegetable shortening (Crisco®), evaporated milk, beef, cheese, creamer and chicken (42).

The relative concentrations of some FAs differ significantly in plasma versus RBCs (Table II). Proportions of ω-3 FAs, 20:4-6 and 18:0, in RBC membrane phospholipids are much higher than those in plasma (50). On the contrary, proportions of 14:0, 16:0, 16:1-7, 18:1-9 and 18:2-6 are much higher in plasma than in RBCs.

Associations with risk factors also differ (Tables III and IV). The associations of RBC FAs differ from those of plasma FAs because (a) they reflect diet over 1–2 months instead of 1–2 days, (b) FAs in RBCs are bound to phospholipids only and (c) they reflect the tissue-selective incorporation of FAs into the RBC membranes. The total plasma FAs reflect those FAs bound to phospholipids and to cholesteryl esters.

The plasma FA profiles related to risk factors in the current study (Table III) are almost identical to those found related to CV mortality in the ULSAM study (3). In the present study, total plasma FA concentrations of saturated FAs (14:0 and 16:0) and those associated with...
high saturated FA consumption (16:1, 18:3-6, and 20:3-6) were in general positively associated with CVD risk factors (triglycerides, LDL-C, HDL-C [negatively], CRP, SBP and DBP, heart rate, BMI, and fasting glucose and fasting insulin, 2-hour glucose and 2-hour insulin), while the polyunsaturated FAs (PUFAs), LA (18:2-6), eicosapentaenoic acid (EPA, 20:5-3) and docosahexaenoic acid (DHA, 22:6-3) were primarily either inversely or not associated with CVD risk factors (Table III).

Discussion
The results support the hypothesis that specific FAs previously identified as related to CV mortality (3) are associated with specific CVD risk factors. The ULSAM investigators found no association between CVD and marine FAs (20:5-3 and 22:6-3), perhaps because these FAs are not well represented in the plasma cholesterol esters they studied (3). For similar reasons, estimates of associations between lipoprotein cholesterol and RBC FAs reported in the current study are of questionable significance because the FAs related to lipoprotein cholesterol are likely bound to plasma lipoproteins (Table III) but not to the RBC FAs in membranes (Table IV) (51–53).

Our results explain and are in agreement with other clinical data. The clinical repercussions of overconsumption of certain saturated FAs are clear. Research has shown that serum FA profiles with high palmitic acid, palmitoleic acid (16:1) and dihomo-γ-linolenic acid (20:3-6), and low proportions of LA (18:2-6) predict myocardial infarction (54,55), stroke (56), left ventricular hypertrophy (57) and metabolic syndrome (21,58,59). It is also known that high saturated FA consumption increases insulin resistance (35,58), glucose intolerance (35,58), metabolic syndrome (58,60) and low-grade inflammation (9,14).

The sources of the clinically relevant FAs in this study population are summarized as follows:

Myristic acid (14:0) comes mostly from store-bought foods (butter, cream, whole milk and tropical oils).

Palmitic acid (16:0) comes mainly from store-bought items (42), but it is also manufactured in the liver (3).

Table I. Population characteristics, Genetics of Coronary Artery Disease in Alaska Natives

|              | Women |          |          |          | Men  |          |          |          |
|--------------|-------|----------|----------|----------|------|----------|----------|----------|
|              | N     | Mean     | SD       | Median   | N    | Mean     | SD       | Median   |
| CVD risk factors |       |          |          |          |      |          |          |          |
| Systolic BP (mmHg) | 419   | 120.60   | (16.8)   | 118      | 336  | 122.35   | (14.2)   | 122      |
| Diastolic BP (mmHg) | 420   | 75.20    | (9.2)    | 74       | 337  | 78.46    | (9.58)   | 79       |
| Mean arterial BP (mmHg) | 419   | 105.47   | (12.9)   | 104      | 336  | 106.94   | (10.71)  | 107.3    |
| BMI (kg/m²) | 419   | 28.65    | (6.2)    | 27.6     | 334  | 26.69    | (5.1)    | 25.6     |
| Waist (cm) | 414   | 89.25    | (14.2)   | 87.63    | 330  | 88.77    | (12.0)   | 86.36    |
| HDL-C (mg/dL) | 419   | 66.94    | (18.7)   | 65       | 337  | 57.39    | (19.0)   | 54       |
| LDL-C (mg/dL) | 419   | 122.43   | (35.1)   | 117      | 337  | 123.11   | (36.6)   | 119      |
| Triglyceride (mg/dL) | 419   | 133.55   | (77.8)   | 114      | 337  | 125.32   | (70.8)   | 107      |
| HbA1c (%) | 421   | 5.51     | (0.46)   | 5.41     | 337  | 5.53     | (0.54)   | 5.5      |
| Fasting glucose (mg/dL) | 421   | 96.79    | (17.8)   | 92       | 337  | 96.81    | (25.1)   | 93       |
| Fasting insulin (µU/mL) | 420   | 10.86    | (7.91)   | 8.85     | 335  | 9.62     | (9.2)    | 7.21     |
| 2-hour glucose (mg/dL) | 282   | 107.54   | (42.4)   | 102      | 237  | 93.35    | (38.4)   | 88       |
| 2-hour insulin (µU/mL) | 280   | 44.86    | (41.9)   | 31.65    | 237  | 28.40    | (37.4)   | 16.4     |
| Heart rate (beats/minute) | 383   | 73.75    | (10.4)   | 72       | 324  | 71.19    | (13.1)   | 70       |
| C-reactive protein | 420   | 0.426    | (1.7)    | 0.12     | 337  | 0.338    | (0.7)    | 0.11     |
| Covariates | |          |          |          | |          |          |          |
| METS | 337   | 56.62    | (58.1)   | 37.51    | 289  | 68.95    | (66.1)   | 49.27    |
| Age (year) | 421   | 51.97    | (12.2)   | 337  | 51.01    | (11.7)   |
| Current smoking (%) | 421   | 53       |          | 337 | 60       |
| Cholesterol medication (%) | 421   | 9.5      |          | 337 | 7.4      |
| BP medication (%) | 421   | 22       |          | 337 | 19       |
| ApoE (n) | 421   | 337      |
| ApoE2 (%) | 1      | 2        |
| ApoE3 (%) | 73     | 66       |
| ApoE4 (%) | 32     | 28       |

Abbreviations: ApoE = apolipoprotein E; BP = blood pressure; BMI = body mass index; CRP = C-reactive protein; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; METS = metabolic equivalents.
This FA has been associated with impaired glucose tolerance and insulin resistance (14,36,57); development of type 2 DM (34,35); and increased BP (35,58), BMI (61), carotid plaque and plaque score (62). The broad effects of this FA on CVD risk factors correspond with data from a pilot study to reduce saturated FA consumption in another cohort of Western Alaska Natives, which resulted in reductions in plasma concentrations of palmitate (16:0), stearate (18:0), LDL-C, fasting glucose, DBP and improved glucose tolerance (35).

**Palmitoleic acid** (16:1) is found in macadamia oil and marine mammals (including seal oil), but it is also a product of endogenous lipogenesis. It is biosynthesized from palmitate by D9D, which is upregulated by saturated fat consumption (3) and behaves like a saturated FA, increasing insulin resistance (14), heart rate (19) and cholesterol (3). In fact, 16:1-7 raises LDL-C more than palmitic acid (16:0) (63). Palmitoleic acid (16:1-7) and its associated D9D activity predicted mortality most strongly in the Swedish cohort, where it was associated with abdominal

---

**Table II.** Fatty acid proportions (% of total fatty acids) as measured in plasma (bold) and red blood cells (black), Genetics of Coronary Artery Disease in Alaska Natives

| Fatty acid   | Male (age in years) | Female (age in years) | p    |
|--------------|---------------------|------------------------|------|
|              | 35-44               | 45-54                  | 55-64 | 65-74 |          | 35-44 | 45-54 | 55-64 | 65-74 | p       |
| Total omega 3| 4.86 5.34 5.94 5.96 | 0.1428                 |      |      | 5.29 5.57 5.77 7.14 | 0.0097 |
| 18:3-3       | 0.56 0.55 0.57 0.61 | 0.8893                 |      |      | 0.6 0.57 0.56 0.64 | 0.4561 |
| 20:5-3       | 1.13 1.3 1.44 1.88  | 0.0444                 |      |      | 1.14 1.36 1.35 1.78 | <0.0001 |
| 22:5-3       | 0.56 0.59 0.6 0.58  | 0.3165                 |      |      | 0.59 0.54 0.51 0.67 | 0.0527 |
| 22:6-3       | 2.14 2.47 2.57 2.7  | 0.0948                 |      |      | 2.45 2.67 2.72 3.52 | 0.0020 |
| C20-C22      | 4.19 4.71 5.15 5.27  | 0.2125                 |      |      | 4.41 4.92 4.93 6.55 | 0.0001 |
| Total omega 6 | 35.06 29.35 27.81 32.32 | 0.3833                |      |      | 30.17 31.27 35.34 29.27 | 0.7880 |
| 18:2-6       | 28.64 28.04 26.82 25.48 | 0.0153                |      |      | 27.57 26.78 24.76 23.84 | <0.0001 |
| 20:4-6       | 1 1.07 0.94 1.08  | 0.2567                 |      |      | 1 1.05 1.02 1.13  | 0.4566 |
| Total MUFA   | 22.95 22.78 24.28 23.21 | 0.8910                |      |      | 22.34 22.79 23.81 23.38 | 0.5446 |
| 16:1-7       | 2.11 2.29 2.3 2.54  | 0.0010                 |      |      | 2.57 2.67 2.76 2.83  | 0.0509 |
| 18:1-9       | 18.96 19.29 19.62 20.1 | 0.3088                |      |      | 18.82 18.9 18.85 18.81 | 0.9951 |
| 20:1-9       | 0.13 0.18 0.17 0.19  | 0.3633                 |      |      | 0.14 0.13 0.13 0.11  | 0.6349 |
| 24:1-9       | 0.24 0.18 0.2 0.21  | <0.0001                |      |      | 0.2 0.2 0.18 0.15  | <0.0001 |
| Total SFA    | 31.9 31.14 31.15 31.74 | 0.3279                |      |      | 32.24 32.51 33.57 33.34 | 0.0375 |
| 14:0         | 0.89 0.88 0.79 0.86  | 0.4904                 |      |      | 0.98 0.97 1.05 1.11  | 0.1615 |
| 16:0         | 23.61 23.09 23.15 23.81 | 0.2858                |      |      | 24.14 24.29 25.15 24.87 | 0.0767 |
| 18:0         | 7.19 7.17 7.21 7.07  | 0.9178                 |      |      | 7.12 7.24 7.38 7.35  | 0.4019 |
| Total trans FAs | 1.61 1.48 1.39 1.45 | 0.1042                |      |      | 1.53 1.7 1.58 1.44  | 0.1539 |
|              | 2.24 2.08 2.09 2.17  | 0.1144                 |      |      | 2.14 2.04 2.03 1.92  | 0.0869 |

---

Citation: Int J Circumpolar Health 2015, 74: 28055 - http://dx.doi.org/10.3402/ijch.v74.28055
| Table III. | Associations\(^a\) between CVD risk factors and total plasma fatty acids (\(\mu g/ml\)), Genetics of Coronary Artery Disease in Alaska Natives |
|-----------------|-------------------------------------------------|
| 0 | 14:0 | 16:0 | 16:1-7 | 18:3-6 | Dihomo-\(\gamma\)-linolenic | 18:0 | 18:1 | 18:2-6 | 20:4-6 | 18:3-3 | 20:5-3 | 22:6-3 |
| 0 | Myristic | Palmitic | Palmitoleic | \(\gamma\)-Linolenic | Stearic | Oleic | Linoleic | Arachidonic | \(\alpha\)-Linolenic | Eicosapentaenoic | Docosahexaenoic |
| Mortality | + | + | + | + | + | NS | + | − | NS | NS | NS | NS |
| Triglyceride | 0.587 | 0.440 | 0.469 | 0.250 | 0.344 | 0.0319 | 0.377 | 0.209 | 0 | 0.421 | 0.119 | 0 |
| (5.2E\(^{-2}\)) | (7.9E\(^{-16}\)) | (1.8E\(^{-23}\)) | (1.4E\(^{-26}\)) | (2.3E\(^{-12}\)) | (4.7E\(^{-15}\)) | (1.4E\(^{-15}\)) | (8.9E\(^{-16}\)) | | | | | |
| LDL-C | 0.115 | 0.169 | 0.205 | NS | 0.113 | 0.235 | 0.198 | 0.249 | 0.217 | 0 | 0.254 | 0.337 |
| (0.03) | (0.002) | (0.000) | (0.031) | (0.0003) | (0.0001) | (1.2E\(^{-16}\)) | (0.0000) | | | | | |
| HDL-C | −0.263 | NS | −0 | NS | NS | NS | −0.137 | NS | NS | −0.146 | NS | NS |
| (4.0E\(^{-1}\)) | (0.028) | (0.009) | (0.009) | (0.009) | (0.009) | (0.009) | (0.009) | (0.009) | (0.009) | (0.009) | (0.009) | (0.009) |
| CRP | NS | NS | NS | NS | NS | NS | NS | NS | NS | −0.108 | (0.026) | NS |
| SBP | 0.096 | (0.031) | 0.097 | (0.029) | NS | 0.110 | (0.023) | 0.137 | (0.002) | NS | NS | NS |
| DBP | 0.114 | (0.013) | NS | NS | 0.115 | (0.021) | 0.107 | (0.021) | NS | NS | NS | NS |
| ABP | 0.107 | (0.018) | 0.101 | (0.024) | NS | 0.118 | (0.015) | 0.143 | (0.002) | NS | NS | NS |
| HR | NS | NS | NS | NS | NS | NS | NS | 0 | NS | −0.168 | (0.0002) | NS |
| BMI | 0.255 | (1.2E\(^{-1}\)) | 0.199 | (0.0003) | 0.172 | (0.001) | 0.174 | (0.001) | 0.197 | (0.0001) | 0.190 | (0.0001) | 0.161 | (0.001) | NS | 0.123 | (0.012) | 0.175 | (0.003) | NS | NS |
| Waist | 0.280 | (1.5E\(^{-15}\)) | 0.209 | (0.0003) | 0.187 | (0.0004) | 0.204 | (0.0002) | 0.193 | (0.0002) | 0.191 | (0.0001) | 0.180 | (0.0002) | NS | 0.137 | (0.006) | 0.166 | (0.005) | NS | NS |
| % fat | 0.268 | (1.2E\(^{-15}\)) | 0.183 | (0.0004) | NS | 0.207 | (0.0001) | 0.198 | (0.0001) | 0.159 | (0.0018) | NS | NS | NS | NS | | NS | NS |
| 2-hour glucose | 0.175 | (0.0002) | 0.166 | (0.004) | 0.200 | (0.0005) | NS | 0.181 | (0.001) | NS | 0.159 | (0.0005) | NS | NS | NS | NS | NS |
| Fasting glucose | 0.100 | (0.003) | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS |
| Fasting insulin | 0.282 | (2.88E\(^{-19}\)) | 0.195 | (0.0003) | NS | 0.137 | (0.0065) | 0.23 | (0.000) | 0.186 | (0.0001) | NS | NS | NS | NS | NS | NS | NS |
| HbA1c | 0.141 | (0.003) | NS | NS | 0.191 | (0.003) | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS |

\(^a\)Results are presented as phenotypic correlation estimate (p-value). Negative associations are shown in bold. All phenotypes are adjusted for age, age\(^2\), sex, age \(\times\) sex, age\(^2\) \(\times\) sex, BMI and physical activity. BMI was not used as a covariate for the BMI analysis. Additional covariates were used as follows: lipid medications for lipids, antihypertensive medication for HR and SBP and smoking for CRP. Mortality data are from Warensjo et al. (3).

BMI = body mass index; BP = blood pressure; CRP = C-reactive protein; DBP = diastolic blood pressure; HDL-C = high-density lipoprotein cholesterol; HR = heart rate; LDL-C = low-density lipoprotein cholesterol; MAP = mean arterial pressure; SBP = systolic blood pressure; NS = not significant.
Table IV. Associations between CVD risk factors and% of total fatty acids in RBCs, Genetics of Coronary Artery Disease in Alaska Natives

|               | 14:0 | 16:0 | 16:1-7 | 18:3-6 | 20:3-6 | 18:0 | 18:1 | 18:2-6 | 20:4-6 | 18:3-3 | 20:5-3 | 22:6-3 |
|---------------|------|------|--------|--------|--------|------|------|--------|--------|--------|--------|--------|
| Mortality     | +    | +    | +      | +      | +      | NS   | +    | +      | NS     | +      | NS     | NS     |
| Triglyceride  | 0.31 (0.0000) | 0.33 (0.0000) | 0.26 (0.0000) | 0.28 (0.0000) | 0.211 (0.0000) | NS   | 0.231 (0.0000) | NS     | NS     | 0.17 (0.003) | -0.315 (0.0000) | -0.20 (0.0005) |
| LDL-C         | NS   | NS   | NS     | -0.146 (0.008) | -0.228 (0.0000) | NS   | NS     | NS     | -0.177 (0.001) | NS     | 0.20 (0.0002) | 0.173 (0.002) |
| HDL-C         | NS   | NS   | NS     | NS     | NS     | NS   | NS     | NS     | NS     | NS     | NS     | NS     |
| CRP           | NS   | 0.091 (0.045) | NS     | NS     | 0.158 (0.0004) | NS   | NS     | NS     | 0.100 (0.037) | NS     | -0.106 (0.018) | -0.113 (0.011) |
| SBP           | NS   | 0.146 (0.006) | NS     | NS     | 0.175 (0.0000) | NS   | 0.109 (0.042) | NS     | NS     | NS     | NS     |
| DBP           | NS   | 0.126 (0.0024) | NS     | NS     | 0.195 (0.0000) | NS   | 0.144 (0.010) | NS     | NS     | NS     | -0.152 (0.007) | -0.117 (0.039) |
| MAP           | NS   | 0.148 (0.006) | NS     | NS     | 0.191 (0.0000) | NS   | NS     | NS     | NS     | NS     | NS     |
| HR            | NS   | NS   | 0.178 (0.0001) | 0.137 (0.002) | NS     | 0.244 (0.0000) | NS   | NS     | NS     | NS     | NS     | NS     |
| BMI           | 0.128 (0.009) | 0.146 (0.003) | NS     | 0.103 (0.039) | 0.091 (0.066) | NS   | NS     | -0.127 (0.009) | NS     | NS     |
| Waist         | 0.161 (0.001) | 0.187 (0.0002) | 0.124 (0.014) | 0.124 (0.015) | 0.100 (0.048) | NS   | NS     | -0.135 (0.007) | NS     | NS     |
| 2-hour glucose| NS   | 0.216 (0.0001) | 0.215 (0.0001) | NS     | 0.118 (0.003) | NS   | NS     | -0.157 (0.005) | NS     | NS     |
| 2-hour insulin| NS   | 0.115 (0.048) | NS     | 0.149 (0.008) | 0.168 (0.004) | NS   | NS     | NS     | NS     | NS     | -0.150 (0.009) |
| Fasting glucose| NS  | NS   | NS     | NS     | NS     | NS   | NS     | -0.103 (0.032) | NS     | NS     |
| Fasting insulin| 0.171 (0.0003) | NS   | NS   | NS   | NS   | NS   | NS     | -0.106 (0.028) | NS     | NS     |

Results are presented as phenotypic correlation estimate (p-value). Negative associations are shown in bold. All phenotypes are adjusted for age, sex, age2, sex, age × sex, age2 × sex, BMI and physical activity. BMI was not used as a covariate for the BMI analysis. Additional covariates were used as follows: lipid medications for lipids, antihypertensive medication for HR and SBP and smoking for CRP.

Mortality data are from Warenso et al. (3).

Fatty acids linked to cardiovascular risk factors.
obesity and triglyceridemia (3). Because D9D catalyses the synthesis of 16:1-7 and 18:1-9 and is upregulated by saturated fat (3), the high intake of saturated fat results in increased lipogenesis and plays a key role in obesity-related diseases (64–66). In the current study, LDL-C was not associated with either RBC phospholipid-bound FAs 16:0 or 16:1, possibly because the phospholipid fractions of the FAs in RBC membranes have little to do with cholesterol metabolism.

Stearic acid (18:0) was not associated with CVD mortality in the Swedish study (3) and was only associated with DBP in the RBC samples in the current study. The relative proportion of 14:0 and 16:0 FAs is higher than 18:0 in meat from corn-fed cattle kept in feedlots than from grass-fed cattle (67), suggesting that the fat in store-bought meat available in village stores has a high proportion of the detrimental FAs 14:0 and 16:0 (42). In the current study, as in other studies, 18:0 appears mainly related to risk factors for obesity and type 2 DM (15).

Gamma-linolenic acid (18:3-6) is mainly a metabolite of 18:2-6 and is the precursor to dihomo-γ-linoleic acid (DHLA; 20:3-6), which is a precursor of arachidonic acid.

Oleic acid (18:1-9) is derived from olive oil, canola, butter, milk, eggs, seal oil and muktuk and can be synthesized de novo from stearic acid by the action of D9D. This FA is generally considered protective or neutral as related to CVD risk (68–70), although some researchers have reported increased CVD risk with higher intake (28). The latter association may be related to the mutual dietary sources of oleic acid and saturated FAs in dairy products, meat and poultry.

Concentration of linoleic acid (18:2-6) in serum is known to reflect dietary intake and is negatively associated with CVD mortality (3) and with a few CVD risk factors (Table IV). The positive association between LA and LDL-C in plasma samples of the current study cannot be explained. LA is known to lower LDL-C (29,30) and decrease risk of myocardial infarction (54). Such protective effects have been noted in clinical and prospective studies (3), and it has been learned in the past few years that FA profiles with low proportions of LA (18:2-6) predict myocardial infarction (4,55), stroke (56), left ventricular hypertrophy (57), insulin sensitivity (14), glucose intolerance (61) and metabolic syndrome (58,60). The conclusion must be that LA is protective (i.e. LA reduces some risk factors, thereby reducing risk for CVD and mortality).

Relative concentrations (%) of alpha-linolenic acid (ALA, 18:3-3) in serum was only marginally (p = 0.06) associated with CV mortality (3) and in this study was associated with increased triglycerides, BMI and 2-hour insulin scores, suggesting that this FA may have some detrimental effects.

Marine omega-3 FAs (EPA, 20:5-3; and DHA, 22:6-3) in RBCs were negatively associated with triglycerides, CRP, DBP, HR and 2-hour insulin, but positively associated with triglycerides and LDL-C in plasma FAs. The ULSAM study found no association between EPA/DHA and CVD mortality, but that could have resulted from looking only at FAs in serum cholesterol esters, which lack high concentrations of these FAs (3). These FAs, in the Alaska Native population, are derived mainly from salmon, sardines, seal oil and whale blubber and are considered cardioprotective, as numerous studies have shown an inverse association with sudden cardiac arrest (28). The conclusion from studies in Greenland, that these FAs prevent atherosclerosis, has recently been cast into doubt as no association has been found with the presence of plaque in Alaska Natives (39). IMT, however, was inversely associated with EPA and DHA (39). The beneficial effects are now believed to be related to reducing arrhythmia (5,18,19,28), which is associated with heart rate, which in turn is negatively associated with RBC and plasma concentrations of EPA and DHA (19).

Differences in FA biomarkers

The results from the 2 FA measures (plasma and RBCs) in the current study and from serum cholesterol ester measures in the ULSAM study (3) are similar in their identification of the FAs that are either detrimental or protective for CV health. Differences between the FA measures, however, are reflected in the associations of FAs with CV risk factors. The current study shows that the 2 measurement methods complement each other. The FA contents of RBCs have poor associations with cholesterol compared with the well-established associations observed with dietary and total serum FA measures (3,32). Plasma measures of saturated FAs were associated with plasma LDL-C concentrations in this cohort, possibly because FAs related to cholesterol are mainly bound to lipoproteins in the plasma. On the contrary, the FAs in serum cholesteryl esters are thought to contain insufficient amounts of marine ω-3 FA to provide reliable associations (3).

Conclusions

High blood concentrations of saturated fats (14:0 and 16:0) are detrimental to cardiovascular health and the biological systems related to it, while some unsaturated FAs (18:2-6, 20:5-3, 22:6-3) are protective.

This study has many strengths. It is the largest population-based survey of CVD and its risk factors in Western Alaska Natives. All methods were carefully standardized and outcomes were ascertained according to American Heart Association/National Heart, Lung, and Blood Institute standard procedures (71). Weaknesses are due to the observational nature of the study, which precludes conclusions of cause and effect. In addition, there may be several dietary and behavioural residual confounders that have not been measured.
The associations between specific FAs and CVD risk factors observed here are consistent with the known relations between FAs and CVD (3). Although these FA biomarkers do not precisely reflect diet, our findings suggest that reducing plasma concentrations of detrimental saturated FAs may in turn improve overall CVD risk status. Reducing palmitate and simple carbohydrate consumption and increasing fish oil consumption could thus lead to a decrease in CVD, MI and stroke. The results, therefore, demand a well-controlled intervention study to reduce plasma concentrations of FAs linked to CVD mortality and CVD risk factors as identified in this article.

Acknowledgements

The authors are grateful to the Norton Sound Health Corporation (NSHC) and the participants of villages participating in this study. We thank Rachel Schaperow, MedStar Health Research Institute, and Mary van Muelken, University of Alaska Fairbanks, for editorial services.

Conflicts of interest and funding

The study was funded by grants R01-HL64244, U01 HL082458 and U01 HL082490 from the National Heart, Lung, and Blood Institute, and by 2U54-NS041069 from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health, Bethesda, MD. WSH is on the scientific advisory board of Aker Biomarine (maker of krill oil) and is the President of OmegaQuant Analytics, LLC, a lab that offers RBC omega-3 testing. None of the other authors have any potential conflicts to report.

References

1. Kritchevsky D. History of recommendations to the public about dietary fat. J Nutr. 1998;128:449–52.
2. Virchow R. Phlogose und thrombose im gefäßsystem. In: Gesammelte abhandlungen zur wissenschaftlichen medizin. Frankfurt: Staatsdruckerei Frankfurt; 1856.
3. Warensjö E, Sundström J, Vessby B, Cederholm T, Risérus U. Markers of dietary fat quality and fatty acid desaturation as predictors of total and cardiovascular mortality: a population-based prospective study. Am J Clin Nutr. 2008;88:203–9.
4. Hu FB, Stampfer MJ, Manson JE, Ascherio A, Colditz GA, Speizer FE, et al. Dietary saturated fats and their food sources in relation to the risk of coronary heart disease in women. Am J Clin Nutr. 1999;70:1001–8.
5. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-prevenzione trial. Lancet. 1999;354:447–55.
6. Markkman P, Gronbaek M. Fish consumption and coronary heart disease mortality. A systematic review of prospective cohort studies. Eur J Clin Nutr. 1999;53:585–90.
7. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. New Engl J Med. 2002;346:1113–8.
8. Howard BV, Best L, Comuzzie A, Ebbesson SOE, Epstein SE, Fabsitz RR, et al. Burden of subclinical infection: insights from the Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study. Diabetes Care. 2008;31:2312–4.
9. Petersson H, Lind L, Huhtke J, Elmgre A, Cerholm T, Risérus U. Relationships between serum fatty acid composition and multiple markers of inflammation and endothelial function in an elderly population. Atherosclerosis. 2009;203:298–303.
10. Grynberg A. Hypertension prevention: from nutrients to (fortified) foods to dietary patterns. Focus on fatty acids. J Hum Hypertens. 2005;19(Suppl 3):S25–33.
11. Stokes J, Garrison R, Kannell WB. The independent contribution of various indices of obesity in the 22-year incidence of coronary heart disease: The Framingham study. In: Vague J, editor. Metabolic complications of human obesity. Elsevier: Amsterdam; 1985. pp. 49–57.
12. Willet WC. Dietary fat plays a major role in obesity: no. Obes Rev. 2002;3:59–68.
13. Vessby B, Unsitupa M, Hermansen K, Riccardi G, Rivelles AA, Tapsell LC, et al. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU study. Diabetologia. 2001;44:312–9.
14. Risérus U. Fatty acids and insulin sensitivity. Curr Opin Clin Nutr Metab Care. 2008;11:100–5.
15. Howard BV, Lee ET, Cowan LD, Fabsitz RR, Howard WJ, Oopik AJ, et al. Coronary heart disease prevalence and its relation to risk factors in American Indians. The Strong Heart Study. Am J Epidemiol. 1995;142:254–68.
16. Ebbesson SOE, Adler AI, Risca PM, Ebbesson LOE, Yeh JL, Go OT, et al. Cardiovascular disease and risk factors in three Alaskan Eskimo populations: The Alaska-Siberia Project. Int J Circumpolar Health. 2005;64:365–86.
17. Fox K, Ford I, Sieg PG, Tendera M, Robertson M, Ferrari R, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction: a subgroup analysis of a randomized controlled trial. Lancet. 2008;372:817–21.
18. Ebbesson SOE, Devereux RB, Lopez-Alvarenga JC, Okin PM, Tejero ME, Harris WS, et al. Heart rate is associated with red blood cell fatty acid concentration: the GOCADAN Study. Am Heart J. 2010;91:1574–83.
19. Ebbesson SOE, Lopez-Alvarenga JC, Okin PM, Devereux RB, Tejero ME, Harris WS, et al. Heart rate is associated with markers of fatty acid desaturation: the GOCADAN Study. Int J Circumpolar Health. 2012;71:17343, doi: http://dx.doi.org/10.3402/ijch.v71i0.17343
20. Gofman JW, Lindgren F. The role of lipids and lipoproteins in atherosclerosis. Science. 1950;111:166–71.
21. Warensjö E, Risérus U, Vessby B. Fatty acid composition of serum lipids predicts the development of the metabolic syndrome in men. Diabetologia. 2005;48:1999–2005.
22. Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med. 2003;348:2082–90.
23. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Contol Clin Trials. 1998;19:61–109.
24. Samaha F, Iqbal N, Seshardri P. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med. 2003;348:2074–81.
25. Brehm B, Seeley R, Daniels S, D'Alessio D. A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low-fat diet on body weight and cardiovascular risk factors in healthy women. J Clin Endocrinol Metab. 2003;88:1617–23.
26. Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review

Citation: Int J Circumpolar Health 2015, 74: 28050 - http://dx.doi.org/10.3402/ijch.v74.28050

Fatty acids linked to cardiovascular risk factors
and meta-analysis. Ann Intern Med. 2014;160:398–406. doi: 10.7326/M13-1788.

27. ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Diaz R, Dyal L, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012; 367:309–18. doi: 10.1056/NEJMoa1203859.

28. Siscovick DS, Lemaître RN, Mozaffarian D. The fish story: a diet-heart hypothesis with clinical applications: m-3 polyunsaturated fatty acids, myocardial vulnerability and sudden death. Circulation. 2003;107:2632–4.

29. Sacks FM, Katan M. Randomized clinical trials on the effects of fats and fatty acids on blood lipids in humans: an overview. Am J Clin Nutr. 1994;60(Suppl):1017S–30.

30. Katan MB, Zock PL, Mensink RP. Effects of fats and fatty acids on blood lipids in humans: an overview. Am J Clin Nutr. 1994;60(Suppl):1017S–22S.

31. Rivellese AA, Maffettone A, Vesby B, Uusitupa M, Hermansen K, Berglund L, et al. Effects of dietary saturated, monounsaturated and n-3 fatty acids on fasting lipoproteins, LDL size and post-prandial lipid metabolism in healthy subject. Atherosclerosis. 2003;167:149–58.

32. de Caterina R, Zampolli A, Del Turco S, Madonna R, Massaro M. Nutritional mechanisms that influence cardiovascular disease. Am J Clin Nutr. 2006;83(Suppl):421S–24S.

33. Sun Q, Ma J, Campos H, Hankison SE, Hu FB. Comparison between plasma and erythrocyte fatty acid content as biomarkers of fatty acid intake in US women. Am J Clin Nutr. 2007; 86:74–81.

34. Ebbesson SOE, Ebbesson LOE, Swenson M, Kennish JM, Robbins DC. A successful diabetes prevention study in Eskimos: the Alaska Siberia project. Int J Circumpolar Health. 2005;64:409–24.

35. Ebbesson SOE, Tejero ME, Lopez-Alvarenga JC, Harris WS, Ebbesson LOE, Devereux RB, et al. Individual saturated fatty acids are associated with different components of insulin resistance and glucose metabolism: the GOCADAN Study. Int J Circumpolar Health. 2010;69:344–51.

36. Maynard JE, Hammes LM, Kester FE. Mortality due to heart disease among Alaskan Natives. 1955–65. Publ Health Rep. 1967;82:714–20.

37. Schumacher C, Davidson M, Ehram G. Cardiovascular disease among Alaskan Natives: a review of the literature. Int J Circumpolar Health. 2003;62:343–62.

38. Cutchins A, Roman MJ, Devereux RB, Ebbesson SO, Umsans JG, Zhu J, et al. Prevalence and correlates of subclinical atherosclerosis in Alaska Eskimos: the GOCADAN study. Stroke. 2008;39:3079–82.

39. Ebbesson SOE, Roman MJ, Devereux RB, Kaufman D, Fabizit RR, MacCluer JW, et al. Consumption of omega-3 fatty acids is not associated with a reduction in carotid atherosclerosis: the Genetics of Coronary Artery Disease in Alaska Natives study. Atherosclerosis. 2007;199:346–53.

40. Trimble B, Hamel R, Gorelick P, Horner R, Longstreth W. Alaska native stroke registry. Int J Stroke. 2007;2:60–1.

41. Risica PM, Nobmann ED, Caulfield LE, Schraer C, Ebbesson SOE. Springtime macronutrient intake of Alaska Natives of the Bering Straits Region: the Alaska Siberia project. Int J Circumpolar Health. 2005;64:222–33.

42. Nobmann ED, Ponce R, Mattil C, Devereux R, Dyke B, Ebbesson SOE, et al. Dietary intakes of Alaskan Eskimo adults of Northwest Alaska, 2000–2003: the GOCADAN study. J Nutr. 2005;135:856–62.

43. Mozaffarian D, Lemaître RN, King IB, Song X, Huang H, Sacks FM, et al. Plasma phospholipid long-chain omega-3 fatty acids and total and cause-specific mortality in older adults: a cohort study. Ann Intern Med. 2013;158:515–25.

44. Baylin A, Campos H. The use of fatty acid biomarkers to reflect dietary intake. Curr Opin Lipidol. 2006;17:22–7.

45. Howard BV, Devereux RB, Cole SA, Davidson M, Dyke B, Ebbesson SO, et al. A genetic and epidemiologic study of cardiovascular disease in Alaska Natives (GOCADAN): design and methods. Int J Circumpolar Health. 2005;64:206–21.

46. Ebbesson SOE, Laston S, Wenger CR, Dyke B, Romnesko T, Swenson M, et al. Recruitment and community interactions in the GOCADAN Study. Int J Circumpolar Health. 2006;65: 55–64.

47. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl 1):S62–9. doi: 10.2337/dc10-0626.

48. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet. 1998;62: 1198–211.

49. Almasy L, Dyer TD, Blangero J. Bivariate quantitative trait linkage analysis: pleotropy versus co-incident linkages. Genet Epidemiol. 1997;14:953–8.

50. Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. Prog Lipid Res. 2008;47:348–80.

51. Vesby B, Aro A, Skarfors E, Berglund L, Salminen I, Lithell H. The risk to develop NIDDM is related to the fatty acid composition of the serum cholesterol esters. Diabetes. 1994;43:1351–7.

52. Erkila A, de Mello VDF, Risérus U, Laaksonen DE. Dietary fatty acids and cardiovascular disease: an epidemiological approach. Prog Lipid Res. 2008;47:172–87. doi: 10.1016/j.plipres.2008.01.004.

53. Lee JS, Pinnanenani SK, Eo SJ, Cho IH, Pyo JH, Kim CK, et al. Saturated, but not n-6 polyunsaturated, fatty acids induce insulin resistance: role of intramuscular accumulation of lipid metabolites. J Appl Physiol. 2006;100:1467–74.

54. Öhrvall M, Berglund L, Salminen I, Lithell H, Aro A, Vesby B. The serum cholesterol ester fatty acid composition but not the serum concentration of alpha tocopherol predicts the development of myocardial infarction in 50-year-old men: 19 years follow-up. Atherosclerosis. 1996;127:65–71.

55. Miettinen TA, Naukkarinen V, Huttunen JK, Mattila S, Kumlin T. Fatty acid composition of serum lipids predicts myocardial infarction. Br Med J (Clin Res Ed). 1982;285: 993–6.

56. Wiberg B, Sundström J, Arnlov J, Terent A, Vesby B, Zethelius B, et al. Metabolic risk factors for stroke and transient ischemic attacks in middle-aged men: a community-based study with long-term follow-up. Stroke. 2006;37: 2898–903.

57. Sundström J, Lind L, Vesby B, Andre B, Aro A, Lithell H. Dyslipidemia and an unfavorable fatty acid profile predict left ventricular hypertrophy 20 years later. Circulation. 2001;103: 836–41.

58. Vesby B. Dietary fat, fatty acid composition in plasma and the metabolic syndrome. Curr Opin Lipidol. 2003;14:15–9.

59. Mayneris-Perxachs J, Guerendiain M, Castellote AI, Estruch R, Covas MI, Fitó M, et al. Plasma fatty acid composition, estimated desaturase activities, and their relation with the metabolic syndrome in a population at high risk of cardiovascular disease. Clin Nutr. 2014;33:90–7.

60. Ebbesson SOE, Tejero MT, Nobmann ED, Lopez-Alvarenga JC, Ebbesson L, Romnesko T, et al. Fatty acid consumption and metabolic syndrome components: the GOCADAN study. J Cardiometab Syndr. 2007;2:244–9.

61. Ebbesson SOE, Kennish J, Ebbesson LOE, Go O, Yeh J. Diabetes is related to fatty acid imbalance in Eskimos. Int J Circumpolar Health. 1999;58:108–19.
62. Ebbesson SOE, Risica PM, Ebbesson LOE, Kennish JM, Tejero ME. Omega 3 fatty acids improve glucose tolerance and components of the metabolic syndrome in Alaskan Eskimos: the Alaska Siberia project. Int J Circumpolar Health. 2005; 64:365–77.

63. Nestel P, Clifton P, Noakes M. Effects of increasing dietary palmitoleic acid compared with palmitic and oleic acids on plasma lipids of hyper-cholesterolemic men. J Lipid Res. 1994; 35:656–62.

64. Risérus U, Árnlov J, Berglund L. Long-term predictors of insulin resistance: role of lifestyle and metabolic factors in middle-aged men. Diabetes Care. 2007;30:2928–33.

65. McGee DL, Reed DM, Yano K, Kagan A, Tillotson J. Ten-year incidence of coronary heart disease in the Honolulu Heart Program. Relationship to nutrient intake. Am J Epidemiol. 1984;119:667–76.

66. Esrey KL, Joseph L, Grover SA. Relationship between dietary intake and coronary heart disease mortality: lipid research clinics prevalence follow-up study. J Clin Epidemiol. 1996;49: 211–6.

67. Daley CA, Abbott A, Doyle PS, Nader GA, Larson S. A review of fatty acid profiles and antioxidant content in grass-fed and grain-fed beef. Nutrition J. 2010;9:10. doi: 10.1186/1475-2891-9-10.

68. Arab L. Biomarkers of fat and fatty acid intake. J Nutr. 2003;133(Suppl 3):925S–32S.

69. Hu FB, Manson JE, Willett WC. Types of dietary fat and risk of coronary heart disease: a critical review. J Am Coll Nutr. 2001;20:5–19.

70. Laaksonen DE, Nyssonen K, Niskanen L, Rissanen TH, Salonen JT. Prediction of cardiovascular mortality in middle-aged men by dietary and serum linoleic and polyunsaturated fatty acids. Arch Intern Med. 2005;165:193–9.

71. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenland K, et al. Heart disease and stroke statistics – 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69–171.